Public Sector Pension Investment Board Increases Position in Integra LifeSciences Holdings Corporation $IART

Public Sector Pension Investment Board raised its position in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 27.3% during the first quarter, according to its most recent filing with the SEC. The firm owned 210,488 shares of the life sciences company's stock after purchasing an additional 45,126 shares during the period. Public Sector Pension Investment Board owned 0.27% of Integra LifeSciences worth $4,629,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IART. LPL Financial LLC acquired a new position in shares of Integra LifeSciences in the 4th quarter worth approximately $255,000. JPMorgan Chase & Co. grew its position in shares of Integra LifeSciences by 130.5% during the 4th quarter. JPMorgan Chase & Co. now owns 199,691 shares of the life sciences company's stock worth $4,529,000 after buying an additional 113,061 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Integra LifeSciences during the 4th quarter worth approximately $943,000. Sterling Capital Management LLC grew its position in shares of Integra LifeSciences by 821.7% during the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after buying an additional 1,931 shares during the period. Finally, First Trust Advisors LP grew its position in shares of Integra LifeSciences by 319.7% during the 4th quarter. First Trust Advisors LP now owns 186,300 shares of the life sciences company's stock worth $4,225,000 after buying an additional 141,907 shares during the period. Institutional investors and hedge funds own 84.78% of the company's stock.

Analyst Upgrades and Downgrades

IART has been the subject of several recent analyst reports. JPMorgan Chase & Co. reduced their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Wells Fargo & Company reduced their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Finally, JMP Securities reduced their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Reduce" and an average price target of $18.63.

Integra LifeSciences Stock Down 2.9%

Shares of NASDAQ:IART traded down $0.43 during trading on Wednesday, reaching $14.26. 1,361,942 shares of the stock were exchanged, compared to its average volume of 1,031,220. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. Integra LifeSciences Holdings Corporation has a 1-year low of $11.06 and a 1-year high of $27.13. The stock has a fifty day moving average of $12.67 and a two-hundred day moving average of $16.64. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -2.18, a price-to-earnings-growth ratio of 0.79 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.02. The company had revenue of $415.61 million for the quarter, compared to analysts' expectations of $395.06 million. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.Integra LifeSciences's quarterly revenue was down .6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.63 earnings per share. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.